• Selection of BBB permeable compounds with high chemical diversity and novelty of structures
• In CNS drug discovery the drug targets are used for targeting CNS and neurological related diseases
like Parkinson’s disease, Alzheimer’s disease, schizophrenia, drug dependence, etc.
• Activity of drug target as a nucleic acid or a protein (e.g. an enzyme, a receptor) can be modulated by
a small-molecular-weight chemical compound.
• As the discovery, identification, characterization and validation of novel human drug targets for CNS
disease biology, and the emergence of new mechanisms and targets for misfolded proteins, tau,
GCPRs, kinase inhibitors, neuroinflammation, etc. continues to grow; this library is a valuable tool for
the neurological and CNS drug discovery.
A unique collection of small molecule compounds selected for the CNS therapeutic area
❑ New chemical structural motifs from the ChemDiv inventory
❑ Recent development in computational models for predicting physico-chemical properties
❑ Recent development in Machine Learning and AI algorithms to predict BBB permeability
❑ CNS BBB Screening Library for the new CNS targets discovery: 23,000 compounds